The effect of Ondansetron on prevention of Ventilator associated pneumonia in ICU

The effect of Ondansetron compared with placebo on prevention of Ventilator associated pneumonia in ICU

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201406156480N6

Enrollment

Registered

2015-10-06

Start date

2011-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia. Pneumonia in diseases classified elsewhere

Interventions

Intervention 1: Intervention group: injection 4 milligram Ondansetron twice a day for 5. Intervention 2: Control group: injection 4 milligram placebo twice a day for 5 days.

Prevention

Placebo

Intervention group: injection 4 milligram Ondansetron twice a day for 5

Control group: injection 4 milligram placebo twice a day for 5 days

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients aged 15-65 years; with the full consent of the patient protector; the patient respiratory support with ventilation; more than 48 hours hospitalization in the ICU Exclusion criteria: patients out of the age range 15-65 years; patients with suspected pulmonary health is arrival; the lack of satisfaction of the patient protector.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ventilator associated pneumonia. Timepoint: Before and 5 days after the intervention, once a day. Method of measurement: Chek list (based on clinical symptoms and laboratory).	—

Secondary

Measure	Time frame
Fever over 38 ° C without any known other infectious focus. Timepoint: Before and 5 days after the intervention, once a day. Method of measurement: Clinical signs.;Leukopenia. Timepoint: Before and 5 days after the intervention, once a day. Method of measurement: Lab data.;Purulent sputum. Timepoint: Before and 5 days after the intervention, once a day. Method of measurement: Clinical signs.;Create new cough or worsening cough previous or shortness of breath or increased respiratory rate. Timepoint: Before and 5 days after the intervention, once a day. Method of measurement: Clinical signs.;Disruption of blood gases. Timepoint: Before and 5 days after the intervention, once a day. Method of measurement: Lab data.	—

Measure

Time frame

Fever over 38 ° C without any known other infectious focus. Timepoint: Before and 5 days after the intervention, once a day. Method of measurement: Clinical signs.;Leukopenia. Timepoint: Before and 5 days after the intervention, once a day. Method of measurement: Lab data.;Purulent sputum. Timepoint: Before and 5 days after the intervention, once a day. Method of measurement: Clinical signs.;Create new cough or worsening cough previous or shortness of breath or increased respiratory rate. Timepoint: Before and 5 days after the intervention, once a day. Method of measurement: Clinical signs.;Disruption of blood gases. Timepoint: Before and 5 days after the intervention, once a day. Method of measurement: Lab data.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hossein Madineh

Shahrekord University of Medical Sciences

hosseinmadineh@yahoo.com+98 38 3333 0061

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 9, 2026